Smoothened inhibitors in the treatment of advanced basal cell carcinomas

Current Opinion in Oncology

Volumn 26, Issue 2, 2014, Pages 184-195

  Kunstfeld, Rainer ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

Author keywords

Basal cell carcinoma; Hedgehog; Smo inhibitors; Smoothened inhibitors

Indexed keywords

ANILIDES; CARCINOMA, BASAL CELL; HEDGEHOG PROTEINS; HUMANS; PYRIDINES; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84894029557     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000058     Document Type: Review

References (32)

1. Caro I, Low JA. The role of the Hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatment. Clin Cancer Res 2010; 16:3335-3339
2. Ng JM, Curran T. The Hedgehog's tale: Developing strategies for targeting cancer. Nat Rev Cancer 2011; 11:493-501
3. Ingham PW, McMahon AP. Hedgehog signaling in animal development: Paradigms and principles. Genes Dev 2001; 15:3059-3087
4. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272:1668-1671
5. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine 1987; 66:98-113
6. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366:2171-2179
7. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366:2180-2188
8. Sekulic A, Migden MR, Basset-Seguin N, et al. Long-Term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study. J Clin Oncol 2013; 31 (Suppl); abstr 9037
9. Grob JJ, Kunstfeld R, Dreno B, et al. Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients. J Clin Oncol 2013; 31 (Suppl); abstr 9036
10. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009; 361:1164-1172
11. Sekulic A, Hauschild A, Migden MR, et al., editors. Survival of patients with metastatic basal cell carcinoma and distant metastasis: The effect of vismodegib, a Hedgehog pathway inhibitor. 8th World Congress of Melanoma; 2013; Hamburg, Germany. This is the first report of survival data of vismodegib in mBCC and distant metastasis
12. Rodon Ahnert J, Baselga J, Tawbi HA, et al. A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. J Clin Oncol 2010; 28 (Suppl); abstr 2500
13. Tawbi HA, Rodon Ahnert J, Dummer R, et al. Phase I study of LDE225 in advanced solid tumors: Updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation. J Clin Oncol 2011; 29 (Suppl); abstr 3062
14. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Investig Dermatol 2011; 131:1735-1744
15. Novartis. Key developments in the fourth quarter of 2011 2011. http://www. novartis.com/downloads/investors/financial-results/q4-2011- innovation-Tables. pdf. [Accessed September 9 2013
16. Siu LL, Papadopoulos K, Alberts SR, et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. J Clin Oncol 2010; 28 (Suppl); abstr 2501
17. Bendell J, Weiss G, Infante J, et al. A phase I dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of LY2940680, an Oral Smo Inhibitor. Eur J Cancer 2012; 47 (Suppl 1); abstr 594
18. Goldman JW, Eckhardt SG, Borad M, et al. Phase 1 dose-escalation trial of the investigational Hedgehog (HH) pathway inhibitor TAK-441 in patients with advanced solid tumors. Ann Oncol 2012; 23 (Suppl 9); abstr 2739
19. Pamlico-Therapeutics. Research and pipeline. http://www.pamlicopharma. com/Home/research. [Accessed September 9 2013
20. Stemline-Therapeutics. Pre-clinical programs. http://stemline.com/pre ClinicalPrograms.asp. [Accessed September 9 2013
21. Rudin CM, Jimeno A, Miller WH, et al. A phase I study of IPI-926, a novel hedgehog pathway inhibitor, in patients (pts) with advanced or metastatic solid tumors. J Clin Oncol 2011; 29 (Suppl); abstr 3014
22. Infinity. Annual Report 2012. http://phx.corporate-ir.net/External.File? item=UGFyZW50SUQ9NTAzMDc5fENoaWxkSUQ9NTQzODAxfFR5cGU 9MQ==&t=1. [Accessed September 9 2013
23. Wagner A, Messersmith W, Shaik N, et al. Phase 1 dose-escalation study of PF-0449913, an oral hedgehog inhibitor in patients with select solid tumors. Eur J Cancer 2012; 48 (Suppl 6); abstr 587
24. Pfizer. Product Pipeline 2013. http://www.pfizer.com/sites/default/files/ product-pipeline/pipeline-2013-0509.pdf. [Accessed September 9 2013
25. Siena Biotech. Le alleanze strategiche, premessa di successo per Siena Biotech 2011 [Strategic alliances, a promise of success for Siena Biotech 2011]. http://euroinfocentre.it/regioni/docs/reg7-Siena Biotech-Russell Thomas-Milan 21-06-11.pdf. [Accessed September 9 2013
26. Kinzel O, Alfieri A, Altamura S, et al. Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo-propyl]-N-(1-phenyl-1H- pyrazol-5-yl)hexahydro-imidazo[1,5-A]pyrazine-7(1H)-carbox amide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2. Bioorg Med Chem Lett 2011; 21:4429-4435
27. Kim J, Tang JY, Gong R, et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 2010; 17:388-399
28. Kim D, Kim J, Spaunhurst K, et al. An open-label, exploratory phase II study of oral itraconazole for the treatment of basal cell carcinoma. Cancer research 2012; 72 (8 Suppl 1); abstr LB-223
29. Bijlsma MF, Spek CA, Zivkovic D, et al. Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLoS Biol 2006; 4: E232
30. DeBerardinis AM, Banerjee U, Miller M, et al. Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway. Bioorg Med Chem Lett 2012; 22:4859-4863
31. The Independent Institute. The Drug Development and Approval Process. http://www.fdareview.org/approval-process.shtml. [Accessed September 16 2013
32. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011; 8:97-106